Immunopeptidomics
What is actually presented? Measure HLA-bound peptides from tissue by mass spectrometry, linked to HLA type, tumor DNA and RNA. Keep the spectra and identification confidence—not just a list of predicted binders.
Same patient.
Two views.
One timeline.
A proposed study connecting measured HLA peptides with mutations tracked over time in the same patients.
Discuss feasibilityLongitudinal mutation tracking
What changes over time? Follow tumor-linked variants through serial plasma or repeat tissue sequencing, with matched normal blood, assay sensitivity and treatment context. A mutation in blood does not by itself establish antigen presentation.
The link is the study.
| Clinical event | Tissue | Blood | Context |
|---|---|---|---|
| Baseline | HLA-peptide measurement + tumor DNA / RNA | Plasma + matched normal / white blood cells | HLA type, pathology, lesion and pretreatment status |
| During follow-up | Repeat tissue only where available and appropriately approved | Serial plasma at protocol-defined visits | Treatment, collection interval and assay detection limits |
| Surgery or progression | Repeat HLA-peptide measurement + DNA / RNA if usable tissue exists | Time-matched plasma; white-cell controls as needed | Residual disease, sampling site and clinical outcome |
Serial blood tracks variants; repeat tissue is needed to assess changes in antigen presentation.
Existing pieces.
A missing connection.
Breast tumor immunopeptidomes
26 primary tumor samplesMeasured HLA peptides and RNA sequencing; PRIDE PXD034818, SRA PRJNA852282.
Gap: No matched longitudinal mutation series established in this release.
View the sourceTNBC evolution during chemotherapy
20 patientsLongitudinal tumor sequencing; BioProject PRJNA396019.
Gap: No measured HLA immunopeptidomics described in this dataset.
View the sourceI-SPY 2 serial ctDNA study
84 patients · 291 plasma samplesPublished longitudinal ctDNA analysis; 58 patients had all four timepoints. Further data or specimen access requires a feasibility and approval process.
Gap: No matching tumor HLA-peptide dataset verified. Residual tissue and variant-level access must be confirmed.
View the sourceThese are published examples, not Tesserie datasets or partners; no complete paired cohort has been verified.
From an introduction
to a feasible study.
Check what overlaps
Start with aggregate counts: patients with suitable tissue, sequencing, serial samples and documented permissions. No patient records are needed for the first conversation.
Co-design a small feasibility study
An investigator and assay lab define the population, tissue requirements, quality checks, costs and decision criteria before committing scarce samples.
Work under institutional governance
Resolve ethics review, consent or applicable waivers, data and material agreements, commercial-use terms and secure analysis before any transfer or new collection.
Is there a fit?
We need an investigator-led cohort, an immunopeptidomics lab and normal or high-risk tissue expertise.
Start with your institution, role and relevant capabilities. We’ll begin with a non-confidential feasibility conversation.
Get startedDo not send patient records, genomic files, raw spectra or identifying information. See our privacy and removal information.